Celldex Trials - LARVOL Sigma

40 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

glembatumumab vedotin (CDX-011) / Celldex

NCT03067935: Individual Patient Expanded Access-Glembatumumab Vedotin

No Longer Available

N/A

glembatumumab vedotin

Celldex Therapeutics

Metastatic gpNMB Expressing Triple Negative Breast Cancer

Rintega (rindopepimut) / Celldex

2012-002272-14: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Studio internazionale randomizzato, in doppio cieco, controllato, di fase II con Rindopepimut/GM-CSF e temozolomide in terapia adiuvante in pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente.

Ongoing

140

Europe

Rindopepimut, KLH, CDX-110, NA, Concentrate for solution for injection/infusion, Sargramostim

CELLDEX THERAPEUTICS, Celldex Therapeutics, Inc.

Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma Pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente, Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente, Diseases [C] - Cancer [C04]

NCT03068650: Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

No Longer Available

N/A

rindopepimut

Celldex Therapeutics

Recurrent GBM

varlilumab (CDX 1127) / Celldex

2017-000302-37: A study to assess the safety and efficacy of the drugs rituximab and varlilumab in patients with B-cell cancer that did not respond to treatment or has returned.

Not yet recruiting

Europe

Varlilumab (as called CDX-1127), Infusion

University Hospital Southampton Foundation Trust

Relapsed or refractory B-Cell malignancies, B-Cell lymphoma in patients who have their disease returning or is resistant to treatment, Diseases [C] - Cancer [C04]

DIAL, NCT03038672: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Active, not recruiting

Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Varlilumab, CDX 1127, CDX-1127, CDX1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer

National Cancer Institute (NCI)

ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

05/23

10/25

ETCTN 10476, NCT04941287: Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active, not recruiting

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cobimetinib, Cotellic, GDC 0973, GDC-0973, GDC0973, MEK Inhibitor GDC-0973, XL 518, XL-518, XL518, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Varlilumab, CDX 1127, CDX-1127, CDX1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer

National Cancer Institute (NCI)

Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma

01/24

04/26

DERIVe, NCT03688178: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting

Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Temodar, TMZ, Temodal, Varlilumab, anti-CD27, Td, Tetanus-diphtheria (Td) toxoid, Td pre-conditioning, Unpulsed DCs, Unpulsed DCs pre-conditioning

Annick Desjardins, MD, Celldex Therapeutics

Glioblastoma

03/26

RiVa, NCT03307746: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma

Completed

1/2

Europe

Varlilumab, Rituximab

University Hospital Southampton NHS Foundation Trust, University Hospital Plymouth NHS Trust, The Christie NHS Foundation Trust, Oxford University Hospitals NHS Trust, Celldex Therapeutics, Cancer Research UK

B Cell Lymphoma

02/21

08/24

Mel-65, NCT03617328: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed

1/2

6MHP, 6 melanoma helper peptide vaccine, Montanide ISA-51, polyICLC, CDX-1127, Varlilumab

Craig L Slingluff, Jr, Celldex Therapeutics

Melanoma

01/24

NCT04081688: Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Active, not recruiting

Atezolizumab 1200 MG in 20 ML Injection, ATEZOLIZUMAB, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Varlilumab 3 mg/kg, CDX 1127, CDX-1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer, VARLILUMAB

Rutgers, The State University of New Jersey, National Cancer Institute (NCI)

Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

04/22

04/24

NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated

IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127

Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)

Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed

12/22

rasdegafusp alfa (CDX-1401) / Celldex

NCT03206047: Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed

1/2

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, CDX-1401, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI 110, SGI-110, SGI110, Laboratory Biomarker Analysis, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid

National Cancer Institute (NCI)

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

11/20

CDX-1140 / Celldex

NCT04536077: Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated

CDX-301, CDX-1140, Research blood draw

Washington University School of Medicine, Celldex Therapeutics, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)

Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer

11/23

NCT06980038: Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Not yet recruiting

Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Agonist CD40 Antibody CDX-1140, Anti-CD40 Agonistic Monoclonal Antibody CDX-1140, CDX 1140, CDX-1140, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Tumor Resection

National Cancer Institute (NCI)

Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8

05/27

NCT05231122: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recruiting

Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Agonist CD40 Antibody CDX-1140, Anti-CD40 Agonistic Monoclonal Antibody CDX-1140, CDX 1140, CDX-1140, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration

Roswell Park Cancer Institute, Merck Sharp & Dohme LLC, Celldex Therapeutics, United States Department of Defense

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma

12/26

FLT3, NCT04491084: Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

Terminated

1/2

FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT

Albert Einstein College of Medicine, Celldex Therapeutics

Non Small Cell Lung Cancer, Lung Cancer

08/22

Mel66, NCT04364230: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed

1/2

6MHP, 6 melanoma helper peptide vaccine, NeoAg-mBRAF, BRAF 585-614 (V600E), PolyICLC, CDX-1140

Craig L Slingluff, Jr, Celldex Therapeutics

Melanoma, Ocular Melanoma, Uveal Melanoma

03/24

NCT05849480: A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting

1/2

oxaliplatin, capecitabine, Keytruda, CDX-1140

National Cancer Institute (NCI)

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct

06/40

06/42

1B-22-2, NCT04616248: In Situ Immunomodulation with CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients W/ Unresectable and Metastatic Solid Tumors

Recruiting

Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Agonist CD40 Antibody CDX-1140, Anti-CD40 Agonistic Monoclonal Antibody CDX-1140, CDX 1140, CDX-1140, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Recombinant Flt3 Ligand, CDX-301, FLT 3 Ligand, FLT3 Ligand, Flt3-Ligand, Flt3L, Mobist, Mobista, rhuFlt3L, Pembrolizumab, Keytruda, Tocilizumab, Actemra

University of Southern California, National Institutes of Health (NIH)

Anatomic Stage IV Breast Cancer AJCC V8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC V8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma

01/26

01/27

NCT04520711: Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting

TCR-transduced T cells, CDX-1140, Pembrolizumab

Providence Health & Services

Malignant Epithelial Neoplasms

02/25

02/27

STU-2021-0657, NCT05029999: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting

PLD Chemotherapy, Pegylated liposomal doxorubicin, CDX-1140, CD40 monoclonal antibody, CDX-301, Flt3 Ligand

University of Texas Southwestern Medical Center, Celldex Therapeutics, Gateway for Cancer Research

HER2-negative Breast Cancer, Metastatic Breast Cancer

04/26

NCT05484011: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated

odetiglucan, Imprime, BTH-1677, Imprime PGG, CDX-1140

HiberCell, Inc., Celldex Therapeutics

Metastatic Pancreatic Adenocarcinoma

03/24

NCT05349890: Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting

TCR-transduced T cells, CDX-1140, Pembrolizumab

Providence Health & Services, Celldex Therapeutics, Providence Cancer Center, Earle A. Chiles Research Institute

Malignant Epithelial Neoplasms

04/26

04/28

Mobista (CDX-301) / Celldex

NCT02839265: FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer

Completed

FLT3 Ligand Therapy (CDX-301), Stereotactic Body Radiotherapy (SBRT), Stereotactic Ablative Radiotherapy (SABR)

Albert Einstein College of Medicine, Celldex Therapeutics

Non-small Cell Lung Cancer (NSCLC)

10/22

11/24

NCT03804944: Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting

100

Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301

Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics

Breast Cancer

12/25

12/27

NCT03789097: Vaccination With Flt3L, Radiation, and Poly-ICLC

Recruiting

1/2

Pembrolizumab, Keytruda, Flt3L, CDX-301, Recombinant Human Flt3 Ligand, Radiation, Poly ICLC, Hiltonol

Icahn School of Medicine at Mount Sinai, Merck Sharp & Dohme LLC, Celldex Therapeutics

Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma

03/25

NCT04930783: NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Recruiting

CDX-301, NEOVAX, Nivolumab, Opdivo, Pembrolizumab, Keytruda

Dana-Farber Cancer Institute, Celldex Therapeutics

Melanoma, Metastatic Melanoma

12/26

09/30

PGV-Prostate, NCT05010200: The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Active, not recruiting

PGV-001, Poly-ICLC, CDX-301

Ashutosh Kumar Tewari

Prostate Cancer

01/27

01/28

barzolvolimab (CDX-0159) / Celldex

EMBARQ-CSU1, NCT06445023: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Recruiting

915

Europe, Canada, US, RoW

barzolvolimab, Matching placebo

Celldex Therapeutics

Chronic Spontaneous Urticaria

10/26

04/27

EMBARQ-CSU2, NCT06455202: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Recruiting

915

Europe, Canada, US, RoW

barzolvolimab, Matching placebo

Celldex Therapeutics

Chronic Spontaneous Urticaria

10/26

04/27

2021-006447-95: NA NA

Ongoing

180

Europe

CDX-0159, CDX-0159, Suspension for injection

Celldex Therapeutics, Celldex Therapeutics Inc., Celldex Therapeutics, Inc.

Chronic Inducible Urticaria, Long-lasting hives with an unknown cause, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Completed

208

Europe, US, RoW

barzolvolimab, CDX-0159, Matching Placebo

Celldex Therapeutics

Chronic Spontaneous Urticaria

09/23

12/24

CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting

196

Europe, US, RoW

barzolvolimab, CDX-0159, Matching Placebo

Celldex Therapeutics, Celldex Therapeutics, Inc.

Chronic Inducible Urticaria

06/24

09/25

NCT06366750: A Study of Barzolvolimab in Patients With Prurigo Nodularis

Recruiting

120

Europe, Canada, US

barzolvolimab, Matching Placebo

Celldex Therapeutics

Prurigo Nodularis

01/26

06/26

NCT06727552: A Study of Barzolvolimab in Patients With Atopic Dermatitis

Recruiting

120

Barzolvolimab, Matching placebo

Celldex Therapeutics

Atopic Dermatitis

10/26

05/27

EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting

Europe, Canada, US, RoW

barzolvolimab, Matching Placebo

Celldex Therapeutics, Celldex Therapeutics, Inc.

Eosinophilic Esophagitis

06/25

12/25

NCT04548869: A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Completed

Europe

CDX-0159

Celldex Therapeutics

Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism, Symptomatic Dermatographism, Cholinergic Urticaria

12/22

05/23

NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis

Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis

Completed

Europe, US

CDX-0159, barzolvolimab, Normal saline

Celldex Therapeutics

Prurigo Nodularis

07/23

CDX-527 / Celldex

CDX527-01, NCT04440943: A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Completed

CDX-527

Celldex Therapeutics

Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors

04/23

BSI-585 / Biosion

NCT05788484: A Study of CDX-585 in Patients With Advanced Malignancies

Completed

CDX-585

Celldex Therapeutics

Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors

05/25

auto-immune therapeutic / Biosion, Celldex

No trials found

ALK.CAR-T / Celldex

No trials found

Undisclosed SCF/KIT bispecific therapeutic / Celldex

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

glembatumumab vedotin (CDX-011) / Celldex

NCT03067935: Individual Patient Expanded Access-Glembatumumab Vedotin

No Longer Available

N/A

glembatumumab vedotin

Celldex Therapeutics

Metastatic gpNMB Expressing Triple Negative Breast Cancer

Rintega (rindopepimut) / Celldex

Ongoing

140

Europe

Rindopepimut, KLH, CDX-110, NA, Concentrate for solution for injection/infusion, Sargramostim

CELLDEX THERAPEUTICS, Celldex Therapeutics, Inc.

NCT03068650: Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

No Longer Available

N/A

rindopepimut

Celldex Therapeutics

Recurrent GBM

varlilumab (CDX 1127) / Celldex

2017-000302-37: A study to assess the safety and efficacy of the drugs rituximab and varlilumab in patients with B-cell cancer that did not respond to treatment or has returned.

Not yet recruiting

Europe

Varlilumab (as called CDX-1127), Infusion

University Hospital Southampton Foundation Trust

Relapsed or refractory B-Cell malignancies, B-Cell lymphoma in patients who have their disease returning or is resistant to treatment, Diseases [C] - Cancer [C04]

DIAL, NCT03038672: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Active, not recruiting

National Cancer Institute (NCI)

05/23

10/25

Active, not recruiting

National Cancer Institute (NCI)

01/24

04/26

DERIVe, NCT03688178: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting

Annick Desjardins, MD, Celldex Therapeutics

Glioblastoma

03/26

RiVa, NCT03307746: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma

Completed

1/2

Europe

Varlilumab, Rituximab

B Cell Lymphoma

02/21

08/24

Mel-65, NCT03617328: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed

1/2

6MHP, 6 melanoma helper peptide vaccine, Montanide ISA-51, polyICLC, CDX-1127, Varlilumab

Craig L Slingluff, Jr, Celldex Therapeutics

Melanoma

01/24

NCT04081688: Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Active, not recruiting

Rutgers, The State University of New Jersey, National Cancer Institute (NCI)

Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

04/22

04/24

NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated

IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127

Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)

Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed

12/22

rasdegafusp alfa (CDX-1401) / Celldex

NCT03206047: Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed

1/2

National Cancer Institute (NCI)

11/20

CDX-1140 / Celldex

NCT04536077: Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated

CDX-301, CDX-1140, Research blood draw

Washington University School of Medicine, Celldex Therapeutics, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)

Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer

11/23

NCT06980038: Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Not yet recruiting

National Cancer Institute (NCI)

05/27

NCT05231122: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recruiting

Roswell Park Cancer Institute, Merck Sharp & Dohme LLC, Celldex Therapeutics, United States Department of Defense

12/26

FLT3, NCT04491084: Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

Terminated

1/2

FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT

Albert Einstein College of Medicine, Celldex Therapeutics

Non Small Cell Lung Cancer, Lung Cancer

08/22

Mel66, NCT04364230: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed

1/2

6MHP, 6 melanoma helper peptide vaccine, NeoAg-mBRAF, BRAF 585-614 (V600E), PolyICLC, CDX-1140

Craig L Slingluff, Jr, Celldex Therapeutics

Melanoma, Ocular Melanoma, Uveal Melanoma

03/24

NCT05849480: A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting

1/2

oxaliplatin, capecitabine, Keytruda, CDX-1140

National Cancer Institute (NCI)

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct

06/40

06/42

1B-22-2, NCT04616248: In Situ Immunomodulation with CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients W/ Unresectable and Metastatic Solid Tumors

Recruiting

University of Southern California, National Institutes of Health (NIH)

01/26

01/27

NCT04520711: Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting

TCR-transduced T cells, CDX-1140, Pembrolizumab

Providence Health & Services

Malignant Epithelial Neoplasms

02/25

02/27

STU-2021-0657, NCT05029999: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting

PLD Chemotherapy, Pegylated liposomal doxorubicin, CDX-1140, CD40 monoclonal antibody, CDX-301, Flt3 Ligand

University of Texas Southwestern Medical Center, Celldex Therapeutics, Gateway for Cancer Research

HER2-negative Breast Cancer, Metastatic Breast Cancer

04/26

NCT05484011: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated

odetiglucan, Imprime, BTH-1677, Imprime PGG, CDX-1140

HiberCell, Inc., Celldex Therapeutics

Metastatic Pancreatic Adenocarcinoma

03/24

NCT05349890: Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting

TCR-transduced T cells, CDX-1140, Pembrolizumab

Providence Health & Services, Celldex Therapeutics, Providence Cancer Center, Earle A. Chiles Research Institute

Malignant Epithelial Neoplasms

04/26

04/28

Mobista (CDX-301) / Celldex

NCT02839265: FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer

Completed

FLT3 Ligand Therapy (CDX-301), Stereotactic Body Radiotherapy (SBRT), Stereotactic Ablative Radiotherapy (SABR)

Albert Einstein College of Medicine, Celldex Therapeutics

Non-small Cell Lung Cancer (NSCLC)

10/22

11/24

NCT03804944: Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting

100

Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301

Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics

Breast Cancer

12/25

12/27

NCT03789097: Vaccination With Flt3L, Radiation, and Poly-ICLC

Recruiting

1/2

Pembrolizumab, Keytruda, Flt3L, CDX-301, Recombinant Human Flt3 Ligand, Radiation, Poly ICLC, Hiltonol

Icahn School of Medicine at Mount Sinai, Merck Sharp & Dohme LLC, Celldex Therapeutics

Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma

03/25

NCT04930783: NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Recruiting

CDX-301, NEOVAX, Nivolumab, Opdivo, Pembrolizumab, Keytruda

Dana-Farber Cancer Institute, Celldex Therapeutics

Melanoma, Metastatic Melanoma

12/26

09/30

PGV-Prostate, NCT05010200: The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Active, not recruiting

PGV-001, Poly-ICLC, CDX-301

Ashutosh Kumar Tewari

Prostate Cancer

01/27

01/28

barzolvolimab (CDX-0159) / Celldex

EMBARQ-CSU1, NCT06445023: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Recruiting

915

Europe, Canada, US, RoW

barzolvolimab, Matching placebo

Celldex Therapeutics

Chronic Spontaneous Urticaria

10/26

04/27

EMBARQ-CSU2, NCT06455202: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Recruiting

915

Europe, Canada, US, RoW

barzolvolimab, Matching placebo

Celldex Therapeutics

Chronic Spontaneous Urticaria

10/26

04/27

2021-006447-95: NA NA

Ongoing

180

Europe

CDX-0159, CDX-0159, Suspension for injection

Celldex Therapeutics, Celldex Therapeutics Inc., Celldex Therapeutics, Inc.

Chronic Inducible Urticaria, Long-lasting hives with an unknown cause, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Completed

208

Europe, US, RoW

barzolvolimab, CDX-0159, Matching Placebo

Celldex Therapeutics

Chronic Spontaneous Urticaria

09/23

12/24

CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting

196

Europe, US, RoW

barzolvolimab, CDX-0159, Matching Placebo

Celldex Therapeutics, Celldex Therapeutics, Inc.

Chronic Inducible Urticaria

06/24

09/25

NCT06366750: A Study of Barzolvolimab in Patients With Prurigo Nodularis

Recruiting

120

Europe, Canada, US

barzolvolimab, Matching Placebo

Celldex Therapeutics

Prurigo Nodularis

01/26

06/26

NCT06727552: A Study of Barzolvolimab in Patients With Atopic Dermatitis

Recruiting

120

Barzolvolimab, Matching placebo

Celldex Therapeutics

Atopic Dermatitis

10/26

05/27

EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting

Europe, Canada, US, RoW

barzolvolimab, Matching Placebo

Celldex Therapeutics, Celldex Therapeutics, Inc.

Eosinophilic Esophagitis

06/25

12/25

NCT04548869: A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Completed

Europe

CDX-0159

Celldex Therapeutics

Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism, Symptomatic Dermatographism, Cholinergic Urticaria

12/22

05/23

NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis

Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis

Completed

Europe, US

CDX-0159, barzolvolimab, Normal saline

Celldex Therapeutics

Prurigo Nodularis

07/23

CDX-527 / Celldex

CDX527-01, NCT04440943: A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Completed

CDX-527

Celldex Therapeutics

04/23

BSI-585 / Biosion

NCT05788484: A Study of CDX-585 in Patients With Advanced Malignancies

Completed

CDX-585

Celldex Therapeutics

05/25

auto-immune therapeutic / Biosion, Celldex

No trials found

ALK.CAR-T / Celldex

No trials found

Undisclosed SCF/KIT bispecific therapeutic / Celldex

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites